GlassScriptPhysician profile
William John Privitera, I
NPI 1275746034
$11,608.95
in general payments reported to CMS, 2019-2025
30 companies · $4,294 in 2025
The $4,294 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $291 · 2021: $334 · 2022: $775 · 2023: $2,396 · 2024: $2,298 · 2025: $4,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,964 · Education: $24.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,964.11 |
| Education | $24.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,858.54 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,502.50 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $1,466.01 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $892.86 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $838.89 | 2019-2025 | Trintellix |
| Lundbeck LLC | $640.16 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $603.92 | 2019-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $591.34 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $520.03 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $452.31 | 2022-2025 | Auvelity |
| Corium, LLC | $424.20 | 2022-2025 | Azstarys |
| Allergan, INC. | $368.20 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $346.56 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $209.37 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $194.39 | 2024-2025 | Qelbree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $151.53 | 2022-2025 | Austedo Xr, Austedo Xr |
| Arbor Pharmaceuticals, INC. | $88.73 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $79.74 | 2023-2025 | Quviviq, Quviviq |
| Acadia Pharmaceuticals INC | $74.86 | 2024-2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $63.57 | 2019 | |
| Noven Therapeutics, LLC | $58.92 | 2024-2025 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $41.86 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.02 | 2025 | Rejoyn |
| Eisai INC. | $24.22 | 2022 | |
| Noven Pharmaceuticals, INC. | $17.43 | 2023 | Xelstrym |
| Lilly USA, LLC | $17.30 | 2025 | Zepbound |
| Tris Pharma INC | $16.14 | 2019 | |
| Adlon Therapeutics L.P. | $14.13 | 2019 | |
| Neos Therapeutics, LP | $12.10 | 2019 | |
| Tms Neurohealth Centers INC. | $7.12 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Privitera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.